ReNetX Bio

ReNetX Bio, a developer of disease-modifying therapies for spinal cord injury (SCI), stroke recovery, and Alzheimer's disease. The company’s disease-modifying therapies provide the Nogo Receptor platform and small-molecule oral compounds that block the binding of β-amyloid (Aβ) oligomers to PrP in the brain, enabling patients with central nervous system disorders to receive appropriate treatment through the stimulation of axonal regeneration.